Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robotic leg device shows promise for helping muscle disease patients walk

NCT ID NCT05199246

Symptom relief Sponsor: Institut de Myologie, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a powered leg exoskeleton (Keeogo) in 50 people with various muscle disorders to see if it is safe and helps them walk better. Participants performed walking tests with and without the device. The goal was to see if the device could improve walking distance and speed without causing harm.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lower-limb powered dermoskeleton (Keeogo exoskeleton)
What this could lead to
If successful, this exoskeleton could help people with muscle weakness walk better and more safely, possibly improving daily mobility.
What could go wrong
This was a small, short-term safety study. The device may not work for all types or severities of muscle disorders, and long-term benefits are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Dec 2021

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years and \< 70 years of age * Height between 1.50 m and 1.95 m * Weight between 45 kg and 110 kg * Abdominal perimeter \< 125 cm * Written informed consent * Affiliate or beneficiary of a social security scheme * Able to comply with all protocol requirements * Confirmed diagnosis of a pathology belonging to one of the following family\*: * Primary disorders of muscles * Muscular dystrophy * Congenital myopathies * Idiopathic inflammatory myopathy * Mitochondrial myopathies * Metabolic disorders * Inborn errors of metabolism * Glycogen storage disease * Functional capacities: * Able to stand up from a chair with armrest without other supports at least 3 times and at most 15 times in 30 seconds. * Report the ability to walk without the assistance of a person at least 2min * The use of traditional orthoses and walking aids will be accepted excepted knee orthoses and walkers (e.g. canes/crutches, ankle foot orthosis). Exclusion Criteria: * Unable to participate in the study * Inability to comply with protocol requirements * Guardianship/trusteeship * Pregnant or nursing women * Unstable Cardiomyopathy * Symptomatic orthostatic hypotension * Medical history of osteoporotic fracture * Balance disorder with extra neuromuscular causes * Recent trauma (fall, accident, ...) * Unstable Cardiomyopathy * Severe respiratory insufficiency

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Congenital myopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy congenital myopathy disorder of glycogen metabolism idiopathic inflammatory myopathy inborn mitochondrial myopathy muscle tissue disorder muscular dystrophy myositis disease neuromuscular disease Thomsen and Becker disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Congenital myopathy Glycogen storage disease Idiopathic inflammatory myopathies Mitochondrial myopathies Muscular dystrophies

Contacts and locations

Locations

  • Institute of Myology

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.